Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Policy / Regulatory

China’s NHC Issues Eye Health Services Work Plan for 2026–2030 – Setting 2030 Targets on Cataract Surgery Rates, Ophthalmologist Workforce Density, and County‑Level Vision Care Capacity

Fineline Cube Sep 9, 2026
Company Drug

Ascletis Pharma Initiates US Phase 1 Study of ASC36 Oral Tablets – An Oral Amylin Receptor Agonist for Obesity, Advancing a Dual‑Format Program Alongside Its Once‑Monthly Injectable

Fineline Cube Sep 9, 2026
Company Drug

Fosun Foundation Donates COVID-19 Therapy Azvudine to Rural China

Fineline Cube Jan 10, 2023

The Fosun Foundation, Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), and Henan...

Policy / Regulatory

NMPA Approves Expanded Production for COVID-19 Symptom Treatments

Fineline Cube Jan 10, 2023

The National Medical Products Administration (NMPA) has approved filings from multiple companies to expand manufacturing...

Company Drug

Roche’s Glofitamab and Dizal’s Sunvozertinib Enter Priority Review

Fineline Cube Jan 10, 2023

The Center for Drug Evaluation (CDE) website indicates that Swiss giant Roche’s (SWX: ROG) glofitamab...

Company Deals

Yinjia Biosciences Raises RMB 100 Million in Series A Financing Round

Fineline Cube Jan 10, 2023

Yinjia Biosciences, a Shanghai-based developer of protein reagents and diagnostic products, has reportedly raised close...

Policy / Regulatory

China Optimizes Medical Insurance Policies for COVID-19 Treatment

Fineline Cube Jan 10, 2023

The National Healthcare Security Administration (NHSA), Ministry of Finance, National Health Commission, and Chinese Center...

Company Deals

China Resources Biopharmaceutical Secures RMB 600 Million in Series B Funding

Fineline Cube Jan 10, 2023

China Resources Biopharmaceutical Co., Ltd has announced the completion of a Series B financing round,...

Company Drug

Adagene’s ADG126 Shows Promise in Combination with Anti-PD-1 Therapy

Fineline Cube Jan 10, 2023

China-based biotech Adagene Inc. (NASDAQ: ADAG), which also operates out of San Diego, California, has...

Company

Pfizer CEO Denies Licensing Paxlovid to Chinese Generics Firms

Fineline Cube Jan 10, 2023

Pfizer Inc. (NYSE: PFE) CEO Albert Bourla, speaking on the sidelines of the JPMorgan Healthcare...

Company

Legend Biotech Receives Nasdaq Notice Regarding Listing Compliance

Fineline Cube Jan 10, 2023

Legend Biotech Corporation (NASDAQ: LEGN) announced on January 6, 2023, that it received a notice...

Company Drug

Jiangxi Jemincare’s JMKX003142 Gets FDA Nod for Clinical Study

Fineline Cube Jan 9, 2023

China-based Jiangxi Jemincare Group has announced receiving approval from the US Food and Drug Administration...

Company Drug Policy / Regulatory

Pfizer’s Paxlovid Excluded from China’s NRDL Amid Price Dispute

Fineline Cube Jan 9, 2023

The National Reimbursement Drug List (NRDL) negotiations have concluded, with Pfizer’s (NYSE: PFE) COVID-19 therapy...

Policy / Regulatory

China Strengthens COVID-19 Prevention and Control in Rural Areas

Fineline Cube Jan 9, 2023

China has intensified its COVID-19 prevention and control measures in rural areas, with the State...

Company Drug

Eli Lilly’s Donanemab Set to Gain Breakthrough Therapy Designation in China

Fineline Cube Jan 9, 2023

The Center for Drug Evaluation (CDE) website indicates that US-based Eli Lilly’s (NYSE: LLY) injectable...

Company Deals

Changzhou Sifary Medtech Secures Series B Funding for Global Expansion

Fineline Cube Jan 9, 2023

Changzhou Sifary Medical Technology Co., Ltd, a China-based platform for the globalization of oral medical...

Company Drug

Suzhou Thery’s Generic Nilotinib Approved by China’s NMPA

Fineline Cube Jan 9, 2023

China-based Suzhou Thery Pharmaceutical Inc. has announced that the National Medical Products Administration (NMPA) has...

Company Drug

Zhifei Biological Products’ BCG Vaccine Filing Accepted by China’s NMPA

Fineline Cube Jan 9, 2023

China-based Chongqing Zhifei Biological Products Co., Ltd (SHE: 300122) has announced that its clinical trial...

Company Drug

Yantai Dongcheng Pharma Gets FDA Go-Ahead for 177Lu-LNC1004 Clinical Trial

Fineline Cube Jan 9, 2023

China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced receiving approval from the...

Company Deals

VivaVision Biotech Partners with Everads Therapy for Retinal Disease Therapies

Fineline Cube Jan 9, 2023

China’s VivaVision Biotech Inc. has announced a collaboration agreement with Israel-based Everads Therapy Ltd to...

Company Deals

Shenzhen-Based Rhegen Bio Raises RMB 100 Million in Pre-Series B Round

Fineline Cube Jan 9, 2023

Shenzhen-based biotechnology company Rhegen Bio, specializing in mRNA technology, has reportedly raised RMB 100 million...

Company Drug

Hainan Poly Pharm’s Generic Ganciclovir Approved in Denmark

Fineline Cube Jan 9, 2023

China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced receiving marketing approval from the...

Posts pagination

1 … 628 629 630 … 718

Recent updates

  • China’s NHC Issues Eye Health Services Work Plan for 2026–2030 – Setting 2030 Targets on Cataract Surgery Rates, Ophthalmologist Workforce Density, and County‑Level Vision Care Capacity
  • Ascletis Pharma Initiates US Phase 1 Study of ASC36 Oral Tablets – An Oral Amylin Receptor Agonist for Obesity, Advancing a Dual‑Format Program Alongside Its Once‑Monthly Injectable
  • Guangzhou Baiyunshan Pharma Wins Registration and Marketing Approval in Macau for Its Freeze‑Dried Rabies Vaccine (Vero Cells) – Joining a Highly Concentrated Supplier Landscape
  • Alebund Pharma Secures US FDA Clinical Trial Approval for AP308 – A First‑in‑Class Recombinant IgA Protease Aimed at a Functional Cure for IgA Nephropathy
  • InnoCare Pharma Secures NMPA Clinical Trial Approval for ICP‑B381 – First Bispecific PSMA/STEAP1 ADC From Its Proprietary Platform, Targeting Prostate Cancer and Other Solid Tumors
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

China’s NHC Issues Eye Health Services Work Plan for 2026–2030 – Setting 2030 Targets on Cataract Surgery Rates, Ophthalmologist Workforce Density, and County‑Level Vision Care Capacity

Company Drug

Ascletis Pharma Initiates US Phase 1 Study of ASC36 Oral Tablets – An Oral Amylin Receptor Agonist for Obesity, Advancing a Dual‑Format Program Alongside Its Once‑Monthly Injectable

Company Drug

Guangzhou Baiyunshan Pharma Wins Registration and Marketing Approval in Macau for Its Freeze‑Dried Rabies Vaccine (Vero Cells) – Joining a Highly Concentrated Supplier Landscape

Company Drug

Alebund Pharma Secures US FDA Clinical Trial Approval for AP308 – A First‑in‑Class Recombinant IgA Protease Aimed at a Functional Cure for IgA Nephropathy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.